Search

The genitourinary syndrome of menopause (GSM) is due to the development of atrophic and dystrophic processes in estrogendependent tissues and structures of the lower third of urinary tract in different periods of aging of the reproductive system. Nonhormonal treatment for GSM is considered as a first-line treatment and includes the use of gels, creams and suppositories that contribute to the restoration of hydrolipid balance, stimulating the collagen production that have an anti-inflammatory, antiseptic, regenerating effect, as well as increasing mucosal resistance and reducing the risk of adhesion of conditionally pathogenic infection. Objective. To evaluate the effectiveness, safety and acceptability of the vaginal cream for intimate hygiene EstrogialTM Plus in women with symptoms of vulvovaginal atrophy (VVA) and GSM. Patients and methods. 24 women aged 43 to 58 were examined. The inclusion criteria were the symptoms of GSM and VVA, the vaginal health index – no more than 20 points. During the course of the study, four visits were carried out, including standard observational procedures, filling the Quality of Life Questionnaire, the administration of treatment. The application of the cream Estrogial™ Plus in doses was prescribed 1 time per day on the vulvar vestibule for 30 days. The effectiveness of therapy was evaluated, all patients continued therapy for up to 60 days. According to the modified questionnaire for general clinical assessment, the state «very much improved» was revealed in 83.3% of patients with a severe form of GSM and VVA and in 66.7% with moderate VVA, «much improved» – in the rest. After treatment, 52% of patients had no symptoms of VVA, and 48% had symptoms in a mild form. Filling the Menopause-Specific Quality of Life Questionnaire (MENQOL), all 24 patients reported positive effects in the form of increased libido and reduced vaginal dryness during sexual intercourses. The study presents clinical cases of cured patients with GSM and VVA. Conclusion. The data obtained during the study make it possible to conclude that the intravaginal administration of the cream EstrogialTM Plus in doses is effective for the treatment of GSM and VVA. The proven therapeutic effects and safety of the use of local non-hormonal treatment enhance the prospects for providing treatment and preventive care for women during the menopausal transition and menopause. Key words: vulvovaginal atrophy, genitourinary syndrome of menopause, non-hormonal treatment, Estrogial™ Plus

Nowadays, a modern trend of the animal husbandry is to increase the reproductive potential of livestock and poultry. There is a large interest worldwide in discovering new and safe non-hormonal biologically active substances obtained from natural sources, which could substitute the synthetic hormones. The positive influence on reproduction in livestock of the biologically active substances of natural origin such as isoflavones, carotenoids, minerals, phytohormones, PUFAs, etc. represent a potential alternative. These substances are derived from various plant sources and micro and macro algae as well. In addition, those substances could provoke positive changes in animal reproduction practices, corresponding to the modern EU requirements for quality and safe for the human health nutrients. The present mini-review summarizes the known in respect of the trend of substitution of the hormonal ones and outlines the potential non-hormonal additives in livestock husbandry.

The objective: to study the clinical efficacy of two schemes of using the monocomponent herbal preparation Cyclodynon® in women of reproductive age with complaints of various menstrual cycle disorders diagnosed with latent hyperprolactinemia and second phase failure of the menstrual cycle based on the results of clinical and hormonal studies. Materials and methods. The study included 60 patients aged 25–38 years suffering from PMS. The main group (n = 30) received Cyclodynon® in an ascending pattern: from 1 to the 14th day of the menstrual cycle – 40 drops 1 time a day and from the 15th day to the end of the cycle – 40 drops 2 times a day. The control group (n = 30) – 40 drops 1 time per day until the end of the cycle for three menstrual cycles. Results. After 3 months in the main group there was a more significant decrease in the level of prolactin (from 28.3 to 18.4 ng / ml) as compared with the control (from 27.8 to 23.1 ng / ml). Increased progesterone and estradiol production was also more significantly observed in the main group. The dynamics of normalization of the duration of the menstrual cycle and the volume of blood loss was also more significant in the main group and amounted to 93.3%. Conclusion. The use of an increasing treatment regimen with Cyclodynon® in women with a luteal phase deficiency on the background of hyperprolactinemia has advantages over the use of a standard continuous regimen with respect to a more rapid normalization of hormonal homeostasis, the duration of the menstrual cycle and blood loss. Key words: luteal phase deficiency, hyperprolactinemia, menstrual disorders, Cyclodynon®.

The article presents the results of the randomized study with the participation of 120 women aged from 45 to 50 years with the metabolic syndrome. The authors determined the levels of the follicle stimulating hormone, luteinizing hormone, estradiol in the dynamics on the background of the application of different combinations of the non-hormonal methods of the correction of the disorders depending on age. On the completion of six months of therapy substantial changes in the hormonal background are revealed in the basic group of patients receiving the non-hormonal complex (diet therapy, psychotherapy, physiotherapy, the therapeutic exercise) and the orally vitamin mineral complex: a decrease in the level FSG to 35,2%, LG- to 25,2%, raising the level of estradiol by 76,3%. The obtained results demonstrate the positive influence of the association of the alternative methods of the correction of climacteric disorders in patients with MS to the hormonal profile. This suggests the pathogenetic justification of the non-drug therapy.

The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all women during the physiological transition from reproductive to post-reproductive life. Though efficacious, hormonal therapy and partial oestrogenic compounds are linked to a significant increase in breast cancer. Non-hormonal treatments are thus greatly appreciated. This systematic review of published hormonal and non-hormonal treatments for climacteric, and breast and prostate cancer-associated hot flushes, examines clinical efficacy and therapy-related cancer risk modulation. A PubMed search included literature up to June 19, 2014 without limits for initial dates or language, with the search terms, (hot flush* OR hot flash*) AND (clinical trial* OR clinical stud*) AND (randomi* OR observational) NOT review). Retrieved references identified further papers. The focus was on hot flushes; other symptoms (night sweats, irritability, etc.) were not specifically screened. Included were some 610 clinical studies where a measured effect of the intervention, intensity and severity were documented, and where patients received treatment of pharmaceutical quality. Only 147 of these references described studies with alternative non-hormonal treatments in post-menopausal women and in breast and prostate cancer survivors; these results are presented in Additional file 1. The most effective hot flush treatment is oestrogenic hormones, or a combination of oestrogen and progestins, though benefits are partially outweighed by a significantly increased risk for breast cancer development. This review illustrates that certain non-hormonal treatments, including selective serotonin reuptake inhibitors, gabapentin/pregabalin, and Cimicifuga racemosa extracts, show a positive risk-benefit ratio. Key points Several non-hormonal alternatives to hormonal therapy have been established and registered for the treatment of vasomotor climacteric symptoms in peri- and post-menopausal women. There are indications that non-hormonal treatments are useful alternatives in patients with a history of breast and prostate cancer. However, confirmation by larger clinical trials is required. Electronic supplementary material The online version of this article (doi:10.1186/s40064-015-0808-y) contains supplementary material, which is available to authorized users.

The development of a new class of non-hormonal contragestational agents provided a derivative, 2-(4-chlorophenyl)-striazole|5,1-alisoquinoline (DL 717-IT or L 12717), with the qualities needed for application in the veterinary field as a post-coital pregnancy-terminating agent. Single intramuscular injections of this compound arrest pregnancy over a wide period of gestation in the bitch. A dose of 2.5 mg/kg was found to be very well tolerated and highly effective (100 per cent) when administered between the day of mating and the 15th day of pregnancy. The desired effect was not accompanied by uterine disorders or other unwanted effects. This non-hormonal agent appears to have several real advantages over the only other drugs (oestrogens) available in veterinary practice for the termination of unwanted pregnancies in bitches.

Bioassay of chromatograms of aqueous potato-sprout and -tuber extracts and lettuce-seed extracts, with the coleoptile, straight-growth test, indicates the presence of a growth promoter running near to the position of IAA and giving a spray colour reaction with Ehrlich reagent similar to that of IAA. It is shown that both promotion and spray colour are due to sugars. It is concluded that major nutrients may give large growth effects in this bioassay and that in certain cases ether extracts may contain quantities of these large enough to give rise to growth effects.